UK Regulator Halts New Prescriptions of Amgen's Tavneos Citing Unreliable Trial Data
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has suspended the use and sale of Tavneos to new patients after determining that the main clinical trial supporting its approval contained unreliable data. CSL Vifor markets the drug in the UK; Amgen holds U.S. rights. The MHRA will revoke the product’s UK approval on March 1, 202…